A deeper investigation into the specific functions and regulatory pathways of Cldn1 in pancreatic cancer is essential to resolve these conflicting observations and develop targeted therapies that could improve patient outcomes. This evidence concerns the gene CLDN1 and familial pancreatic carcinoma.